CD19 and mantle cell lymphoma: The clinical development of CAR-T cell therapy for hematologic malignancies was exampled by the recent approval of CD19-targeting KTE-X19, brexucabtagene autoleucel, for a new indication, the mantle cell lymphoma (MCL).